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The BASIL survival prediction model in patients
with peripheral arterial disease undergoing
revascularization in a university hospital setting
and comparison with the FINNVASC and
modified PREVENT scores
Paul W. Moxey, MD, MRCS, Jack Brownrigg, BSc, Sharanya S. Kumar, BSc, Georgina Crate, BSc,
Peter J. Holt, PhD, FRCS, Matt M. Thompson, MD, FRCS, Keith G. Jones, MS, FRCS, and
Robert J. Hinchliffe, MD, FRCS, London, United Kingdom
Background: Critical limb ischemia carries a significant risk of morbidity and mortality. The development of scores to
predict risk can aid clinical decision making. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial
investigators developed a model to predict death, which has not been previously validated.
Methods:Data were collected in a prospectively maintained database on all patients who underwent angioplasty or arterial
bypass for peripheral artery disease in a university hospital between January 2008 and June 2010. The main outcome
measures were all-cause mortality and amputation-free survival at 3, 6, 12, and 24 months after the index intervention.
The BASIL survival predictor, Finland National Vascular (FINNVASC) registry, and Edifoligide for the Prevention of
Infrainguinal Vein Graft Failure (PREVENT) models were applied and receiver-operating characteristic (ROC) curve
analysis was used to evaluate their predictive power.
Results:Data on 342 patients were collected. Patients with isolated iliac disease or claudication were excluded. The 6-, 12-,
and 24-month all-cause mortality rates were 11.6%, 17.9%, and 26.8%, respectively. The area under the ROC curve (95%
confidence interval) using the BASIL score to predict mortality at 6, 12, and 24months was 0.700 (0.60-0.80; P< .001),
0.651 (0.56-0.74; P < .003), and 0.681 (0.59-0.74; P < .001), respectively. ROC curve analysis indicated that the
performance of the BASIL score in this cohort was comparable to other validated predictive scores.
Conclusions: The BASIL survival predictionmodel can moderately predict short-term andmedium-termmortality in patients
with limb ischemia and may be a useful adjunct to decision making in everyday clinical practice. (J Vasc Surg 2013;57:1-8.)
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tSevere limb ischemia (SLI) carries a significant risk of
morbidity and mortality. The development of scores to
predict death can aid clinicians in decision making, guide
the appropriate use of health care resources, and allow a
meaningful comparison of outcomes between clinicians
and institutions. Data from the Finland National Vascular
(FINNVASC) registry and Edifoligide for the Prevention
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ave informed two risk-scoring methods for amputation-
ree survival (AFS)1,2 that have demonstrated external va-
idity in predicting 1-year AFS in cohorts with critical limb
schemia (CLI) only.3 Each uses a different mix of input
ariables to produce its output, which is a stratification
core or the predicted percentage mortality (Table I).
In the Bypass versus Angioplasty in Severe Ischaemia of
he Leg (BASIL) trial, patients with SLI were randomized
o a revascularization strategy of bypass surgery first or
alloon angioplasty first.4 BASIL investigators developed a
odel to predict death at 6, 12, and 24 months based on
ata from their study population of 452 patients, which has
ot been previously validated.5 The factors that contrib-
ted to the survival model were age, presence of tissue loss,
erum creatinine, number of ankle pressure measurements
etectable, maximum ankle pressure measured, a history of
yocardial infarction or angina, a history of stroke or
ransient ischemic attack, below-knee Bollinger angiogram
core, body mass index, and smoking status. The present
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January 20132 Moxey et alstudy sought to determine the validity of this survival
prediction model in patients undergoing infrainguinal by-
pass or angioplasty.
Scoring systems are often developed from highly se-
lected populations of patients, but to be clinically relevant
to everyday practice, they must be applicable to broader
populations. We sought to validate the BASIL scoring
system in a single-center population of patients in South
London, England, to assess its applicability to everyday
vascular practice as a means of stratifying risk to inform
clinicians and patients of the outcome of lower limb revas-
cularization.
METHODS
Data on all patients undergoing angioplasty or bypass
for limb ischemia in a university hospital vascular depart-
ment between January 2008 and June 2010 were retro-
spectively reviewed. A pragmatic multidisciplinary decision
wasmade in determining whether a patient should undergo
bypass surgery or angioplasty as assessed by the anatomic
distribution of peripheral artery disease (PAD), cardiorespi-
ratory fitness, and the burden of other comorbidities. To be
included, patients must have undergone a lower limb by-
pass surgery or angioplasty for CLI, as defined by the
Trans-Atlantic Inter-Society Consensus (TASC) II guide-
lines.6 Our predefined inclusion criteria specified patients
with a preintervention angiogram andminimum 12-month
duration of follow-up. Data on all prior, index, and repeat
interventions, along with baseline clinical characteristics
and medications, angiographic studies, and clinical out-
comes were collected. Preintervention below-knee diag-
nostic angiograms were scored according to the Bollinger
method7 and simplified to a value of5 or5 according to
the BASIL survival prediction model.
Outcomes were defined according to the Society for
Vascular Surgery lower limb reporting criteria.8 A reinter-
vention was defined as any revascularization procedure
attempted on the same limb as the index procedure. Patient
death was ascertained by reviewing clinical records and, in
the case of patients who were still alive after the last clinic
Table I. Comparison of the components and output syste
of Infrainguinal Vein Graft Failure (PREVENT) III, and B
(BASIL) scoring systems
FINNVASC PR
Variables One point for each of
Diabetes mellitus
Foot gangrene
Coronary artery disease
Urgent operation
Dialysis
Tissue lo
Age  7
Coronar
Output method Risk stratified 1-4 on sum
of points
3 poin
4-7 poin
8 poin
Externally validated Yes (Arvela et al3) Yes (Schcontact, primary care records. All patients were routinely oiven statin and antiplatelet medication after the procedure
nless contraindicated. The BASIL Survival Predictor (http://
asiltrial.com/survival_predictor.htm), Finland National Vas-
ular (FINNVASC)AFS andmodified PREVENTAFSmod-
ls were applied to the validation cohort (Table I).
All-cause mortality rates at 6, 12, and 24 months after
he index intervention were the primary end points. The
ccuracy of the BASIL model score in predicting death at
hese postoperative intervals was assessed using receiver-
perating characteristic (ROC) curves.9 The area under the
OC curve (AUC) for the BASIL score was compared with
he AUC for the FINNVASC and PREVENT AFS scores.
ptimal cutoff points on the ROC curve were chosen at a
hreshold with the best compromise between high sensitiv-
ty and specificity. All statistical analyses were performed
sing SPSS 16.0 software (SPSS Inc, Chicago, Ill).
In secondary analyses, we applied the BASIL and other
isk scores to the nonselective cohort before patients with
isabling claudication and patients with isolated iliac dis-
ase were excluded.
ESULTS
Data on 342 patients were collected during the study
eriod (January 2008 to June 2010). We excluded 99
atients who underwent revascularization for disabling
laudication only and a further 23 patients with isolated
liac artery disease. The 223 patients in the remaining
alidation cohort with CLI and infrainguinal peripheral
rterial disease were a mean age of 72.6 years, and 149
66.5%) were men (Table II).
The all-cause mortality rates were 11.6%, 17.9%, and
6.8% at 6, 12, and 24 months, respectively, compared
ith mean prediction model scores of 14.1%, 21.6%, and
2.0%. Perioperative (30-day) mortality was 3.6% (8 of
23). Follow-up was a mean duration of 29  7 months
range, 12-41 months). AFS was 90.2% (202 of 224) at 30
ays and 71.9% (161 of 223) at 12 months.
Overall, 156 of the 223 patients (70.0%) in the valida-
ion cohort underwent angioplasty during the index admis-
ion. After exclusion of four patients who received bypass
the Finland National Vascular (FINNVASC), Prevention
s versus Angioplasty in Severe Ischaemia of the Leg
NT III (PIII) BASIL
oints
3 points
rs  2 points
ry disease  1 point
Tissue loss
Body mass index
Creatinine Bollinger score
Age Smoking
Coronary artery disease
Ankle pressure
low risk
medium risk
high risk
6, 12 and 24 month % mortality
calculated by model
(http://basiltrial.com/survival_
predictor.htm)
et al2; Arvela et al3) Nom of
ypas
EVE
 4 p
ss 
5 yea
y arte
ts 
ts 
ts perations without preoperative angiographic studies, the
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Volume 57, Number 1 Moxey et al 3validation cohort contained 67 patients (30.0%) who un-
derwent bypass (Fig 1). In 197 of 223 patients (88.3%), the
intervention on the index admission was the first on that
limb; however, 26 (11.7%) underwent repeat procedures
(redo or revision). These patients underwent duplex ultra-
sound imaging before bypass surgery.
The AUC (95% confidence interval [CI]) with the
BASIL survival predictor score used to predict 6-, 12-, and
24-month mortality was 0.700 (0.60-0.80; P  .001),
0.651 (0.56-0.74; P  .003), and 0.681 (0.59-0.74; P 
.001), respectively (Fig 2). At 30 days, the AUC for the
FINNVASC AFS score was 0.581 (95% CI, 0.437-0.725;
P  .222). The modified PREVENT score for 12-month
AFS was superior (AUC, 0.582; 95% CI, 0.497-0.666; P
.000) to the corresponding FINNVASC score (0.543; 95%
CI, 0.458-0.628; P  .001; Figs 3 and 4, Table III).
In secondary analyses, we applied the BASIL and other
risk scores to the nonselective cohort before exclusion of
patients with disabling claudication and those with isolated
iliac disease. In this larger cohort of 342 patients, the 6-,
12-, and 24-month all-cause mortality rates were 9.6%,
15.2%, and 23.8%, respectively. The AUC using the BASIL
score to predict 6-, 12-, and 24-month mortality was
0.697, 0.669, and 0.681, respectively. The FINNVASC
score performed better in the nonselective cohort, with an
AUC of 0.609 for 30 days AFS. The modified PREVENT
Table II. Baseline clinical characteristics
Variables
Validation cohort (n  223)
Mean  SD or No. (%)
Age, years 72.6  13.2
Sex
Male 149 (66.5)
Female 75 (33.5)
Body mass index, kg/m2 25.7  4.9
Creatinine, mol/L 117.85  109.2.0
CRF requiring hemodialysis 15 (6.7)
Smoking history 149 (66.5)
Ischemic heart disease 69 (30.8)
Cerebrovascular disease 52 (23.2)
Hypertension 186 (83.4)
Hypercholesterolemia 142 (63.4)
Diabetes 108 (48.2)
Medications at admission
ACE inhibitor or ARB 131 (58.5)
-blocker 50 (22.3)
Aspirin or clopidogrel 144 (64.3)
Statin 160 (71.4)
Presenting complaint
Rest pain 78 (34.8)
Tissue loss 146 (65.2)
Bollinger score 5 155 (69.2)
Level of revascularization
Femoropopliteal 142 (63.7)
Crural 49 (22.0)
Pedal 10 (4.5)
Multilevel 21 (9.4)
ACE, Angiotensin-converting enzyme; ARB, angiotensin II-receptor
blocker; CRF, chronic renal failure; SD, standard deviation.score for 12-month AFS also demonstrated improved ac- turacy in the nonselective cohort, with an AUC of 0.641 at
2 months.
ISCUSSION
The 2-year survival in the present series was 73%,
omparable with the 70% survival at 2 years observed in the
ASIL trial. Our results for the BASIL model, which has
ot been previously validated, suggest the BASIL scoring
ystem can predict survival of patients undergoing interven-
ion for CLI with a moderate degree of sensitivity and
pecificity. The model demonstrated fair performance in a
alidation cohort containing patients with CLI (according
o TASC II definition) and was best in the prediction of
-month mortality where the AUC value was highest
0.700). It is noteworthy that when the BASIL score was
valuated in patients with diabetes only, its predictive per-
ormance improved (AUC of 0.769 for 6-month mortality;
able III). This is particularly significant, given that most
mputations in the United States are performed in patients
ith diabetes.10
The BASIL survival prediction functions overestimated
eath in our validation cohort at 6, 12, and 24 months, the
easons for which are not clear. A greater provision of
ntiplatelet and lipid therapy in this cohort compared with
he BASIL cohort will likely contribute to preventing car-
iovascular disease events and improving survival. Despite a
igh prevalence of clinically significant cardiovascular dis-
ase in the BASIL derivation cohort, one-third of patients
ere not receiving an antiplatelet agent and only one-third
ere receiving a statin. Improvement is seen in this valida-
ion cohort with the use of antiplatelet agents (64%), statins
71%), and other cardioprotective medications. All patients
hould have been receiving these proven preventers and
ote should be taken of the lower-than-expected rate of use
een in the cohort. These data are similar to those from the
eduction of Atherothrombosis for Continued Health
REACH) registry that suggested most outpatients with
AD receive inadequate medical therapy. This overestima-
ion would likely be corrected by a calibration process to
roduce better agreement between predicted and actual
ortality. Importantly, coexisting coronary artery disease
nd cerebrovascular disease represent the major cause of
eath in patients with PAD.11
The BASIL investigators asked clinicians in participat-
ng centers to enroll patients with SLI and a pattern of
isease that could be equally well treated with a bypass
urgery-first or angioplasty-first strategy. The lack of well-
efined criteria for randomization has led to criticism of the
election process in the BASIL trial, which was felt to be a
ighly selected cohort. An audit of the top six recruiting
enters found just 48 of 456 patients (11%) with CLI due
o infrainguinal disease were randomized, meaning the
erivation cohort for the survival model was a select group.
ur validation study included a secondary analysis to eval-
ate the performance of the BASIL score in a nonselective
ohort of patients. We observed broadly similar outcomes
o BASIL in a secondary cohort that included patients with
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January 20134 Moxey et alclaudication and iliac disease. Furthermore, the BASIL
score appeared to perform well in this nonselective cohort.
The applicability of the BASIL model in a broad range
of patients reflective of routine clinical practice is clinically
useful given that many attempts at infrainguinal revascular-
ization fail12 and that the rate of reinterventions and am-
putation in this patient population is high due to recurrence
at the revascularized site and new-onset remote disease. On
the basis of the observed increase in morbidity and the
expense associated with bypass in short-term follow-up,
data from the BASIL trial suggest that CLI patients who are
likely to live for 2 years could be better treated with
angioplasty. This recommendationmay equally apply in the
setting of recurrent disease, where it will also be useful to
predict mortality to aid decision making for the revascular-
ization strategy.
A major limitation of the BASIL score is the need for
angiographic data to produce the Bollinger score needed to
input into the model. This involves an invasive intervention
not required in the other scores and could severely limit the
general applicability of the score in everyday vascular prac-
tice in institutions where percutaneous angiography is not
routinely performed. An invasive procedure would be inap-
propriate in a patient in whom conservative management is
most likely, and therefore, this score is only applicable in
patients in whom surgery is planned. In our institution,
percutaneous angiography is the preferred modality for the
investigation of critically ischemic limbs when considering
revascularization, and therefore, the Bollinger score could
 
 
 
 
 
 
 
 
 
92 underwent bypass surger
  74 primary interventions 
  10 secondary interventions 
 
291 patients wit
infra-inguinal 
disease 
9 required 
reintervention 
3 (3.5%) 
died at 30 days 
60/85 (70.6%) 
with AFS at 1 
year 
7 excluded: 
bypass planned 
on duplex US  
46/73 (63.0%) 
with AFS at 2 
years 
Fig 1. Consolidated Standards of Reporting Trials diag
AFS, Amputation-free survival; US, ultrasound.be obtained retrospectively in most patients. Comparison pf the BASIL score strength with and without the inclusion
f angiographic data would be of interest but is beyond the
cope of this study.
The derivation cohorts for the three scoring systems
resently discussed differed with respect to the inclusion
nd exclusion criteria applied and the patient populations
romwhich they were derived (Table IV). These differences
hould be taken into consideration when interpreting and
omparing the predicted outcomes derived from each
odel. PREVENT III investigators derived their risk strat-
fication score from 1404 patients who underwent vein
ypass for critical limb ischemia. Validation studies suggest
he PREVENT III score is a reliable tool for stratifying
atients according to risk of major amputation or death at 1
ear with one study of a cohort of 1425 patients from a
ingle institution reporting an AUC of 0.634 for the pre-
iction of 1-year AFS.3 The FINNVASC score, derived
rom data after infrainguinal revascularization in 3925 pa-
ients at Finnish institutions, has also demonstrated validity
n external cohorts.
The predictive performance of the FINNVASC and
REVENT scores was comparable to the BASIL score in
ur validation cohort. When considering the applicability
f scoring systems to clinical practice, it is generally ac-
epted that models with an AUC value of 0.7 should be
sed with caution.13 The BASIL score yielded AUC values
arying from 0.66 to 0.77, which compare favorably with
hose from the FINNVASC (0.51-0.73) and PREVENT
0.53-0.64) models. Despite this modest improvement in
257 underwent angioplasty: 
  226 primary interventions 
  32 secondary interventions 
25 required 
reintervention 
8 (3.1%) died at 
30 days 
193/257 (75.1%) 
with AFS at 1 
year
58 patients with 
isolated iliac 
disease 
162/247 (65.6%) 
with AFS at 2 
years
hows consecutive patients included in the total cohort.y: 
h 
ram serformance, the BASIL model incorporates more com-
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Volume 57, Number 1 Moxey et al 5Fig 2. Receiver-operating characteristic curve (ROC) is shown
for predicting all-cause mortality at 6, 12, and 24 months in the
validation cohort (n  223) by the Bypass versus Angioplasty in
Severe Ischaemia of the Leg (BASIL) survival predictor. Fig 3. Receiver-operating characteristic (ROC) curve is shown
or predicting amputation-free survival (AFS) at 30 days and 12
onths by the Finland National Vascular (FINNVASC) registryig 4. Receiver-operating characteristic (ROC) curve is shown
or predicting amputation-free survival (AFS) at 12 months by the
odified Edifoligide for the Prevention of Infrainguinal Vein Graft
ailure (PREVENT) score.
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January 20136 Moxey et alplex variables that may not always be readily available to
clinicians, which may limit its applicability to general vas-
cular practice. Although the FINNVASC and PREVENT
models were originally developed to predict outcome after
surgical revascularization in patients presenting with CLI
and infrainguinal disease, we found they were superior
when applied to a nonselective cohort of patients.
As with all scoring systems, the estimated risk data
produced will contain a degree of error, and no model
should be used in isolation to replace clinical judgment and
expertise. Outcomes after lower limb revascularization, in
particular, are subject to a large number of variables that no
statistical model can completely adjust for. They can, how-
ever, act as a useful adjunct to clinical decision making and
aid in the multidisciplinary approach to the management of
the critically ischemic limb.
This study has some limitations. St George’s Hospital
NHS Trust was one of the original 27 units recruiting
patients into the BASIL trial, and it could be argued that
bias and patterns of care from this institution would influ-
ence the validation process. In mitigation, however, BASIL
recruitment ended 8 years ago (2004), and many of the
original clinicians involved in the management decisions at
that time are no longer performing lower limb revascular-
ization at St George’s Hospital. We included all consecu-
Table III. Comparison of area under the receiver-operatin
cohort for Bypass versus Angioplasty in Severe Ischaemia o
and modified Edifoligide for the Prevention of Infrainguin
Variablea 30 days 6
BASIL
Survival 0.700
Survival (DM only) 0.769
FINNVASC
Survival 0.581 (0.44-0.73)
AFS 0.576 (0.34-0.81)
AFS (bypass only)
AFS (DM only) 0.732 (0.58-0.88)
Modified PREVENT 0.578 (0.44-0.72)
Survival 0.537 (0.27-0.80)
AFS
AFS (bypass only)
AFS (DM only)
AFS, Amputation-free survival; CI, confidence interval; DM, diabetes mellit
aData are presented as area under the ROC curve (95% CI).
Table IV. Key characteristics of study cohorts
Score Intervention
BASIL Infrainguinal angioplasty or bypass
FINNVASC Infrainguinal surgical revascularizatio
PREVENT Infrainguinal bypass with autologous
Validation cohort Infrainguinal angioplasty or bypass
CLI,Critical limb ischemia; BASIL,Bypass versus Angioplasty in Severe Ischa
for the Prevention of Infrainguinal Vein Graft Failure; SLI, severe limb isch
aIncluding femoral endarterectomy, femoropopliteal, and infrapopliteal byptive revascularizations in this study, whereas enrollment in oASIL was selective, resulting in low numbers from each
nstitution.
In the BASIL survival prediction model, the ankle
ressures are one of the nine components of the score.
nfortunately, ankle-brachial pressure indexes (ABPIs)
ere poorly recorded in our lower limb revascularization
atabase, and these data were missing; however, we have a
arge population of patients with diabetes and chronic
idney disease in whom ABPIs are known to be spuriously
igh. Our BASIL scores are therefore calculated without an
BPI, which is allowed in the workings of the model. The
ignificance of these missing data on the BASIL score is
nknown.
ONCLUSIONS
The BASIL survival prediction model was able to mod-
rately predict short-term and medium-term mortality in a
elected population of patients presenting to a university
ospital requiring revascularization and could, therefore,
e suitable for use in routine vascular practice. Use of this
odel may aid decision making with regards to treatment
ptions (including bypass, angioplasty and more conserva-
ive approaches) and estimation of prognosis, but in its
urrent form, cannot be used exclusively or at the expense
aracteristic (ROC) curve for subgroups of the studied
Leg (BASIL), Finland National Vascular (FINNVASC),
in Graft Failure (PREVENT) scores
ths 12 months 24 months
0-0.80) 0.651 (0.56-0.74) 0.664 (0.59-0.74)
3-0.91) 0.717 (0.60-0.83) 0.668 (0.55-0.79)
0.533 (0.45-0.62)
0.506 (0.41-0.60)
0.543 (0.46-0.63)
0.548 (0.39-0.71)
0.582 (0.48-0.68) 0.627 (0.54-0.71)
0.582 (0.50-0.67)
0.595 (0.44-0.75)
0.581 (0.45-0.71)
Inclusion
SLI (Rutherford 4-6)
CLI (Fontaine III/IV)
CLI (Rutherford 4-6  hemodynamic corroboration)
CLI (Rutherford 4-6)
f the Leg; FINNVASC, FinlandNational Vascular; PREVENT, Edifoligideg ch
f the
al Ve
mon
(0.6
(0.6
us.na
vein
emia of clinical experience.
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lag; 2001.ubmitted Oct 17, 2011; accepted Apr 23, 2012.INVITED COMMENTARYJoseph L. Mills, Sr, MD, Tucson, Ariz
This interesting manuscript from the respected St George=s
Vascular Institute evaluated three different models of risk pre-
diction in a single institution=s population of patients with
severe (critical) limb ischemia (CLI) who underwent revascu-
larization, of which, 35% had ischemic rest pain and the remain-
ing 65% had tissue loss. Survival and amputation-free survival
(AFS) were analyzed by applying predictive factors from the
Bypass Versus Angioplasty in Severe Ischemia of the Leg
(BASIL), the national vascular registry in Finland (FINNVASC), and
Edifoligide for the Prevention of Infrainguinal Vein Graft Failure
(PREVENT) III models. A concise table created by the authors
nicely compares the relevant factors in eachmodel for those readers
who may not be familiar with them. Receiver operator character-
istic (ROC) curve analysis was used to evaluate relative predictive
power.
The premise of this study no doubt stems from the observa-
tion in the BASIL trial that patients who survived 2 years fared
better with bypass than with endovascular therapy.1 Thus, identi-
fying CLI patients before intervention who are unlikely to survive
long enough to benefit from aggressive revascularization or un-
likely to salvage their limbs, even with such intervention, would be
clinically useful.
The authors= analysis concluded that all three models were
modest predictors of short-term and intermediate-term survival
and of short term AFS, with area-under-the-ROC-curve values
ranging from 0.54-0.72, depending on the end point and
follow-up time. As the authors acknowledge, area-under-the-ROC
values 0.7 should be used with caution, and although perhaps
clinically useful, the models in their “current form cannot be used
exclusively at the expense of clinical” judgment.omprise a heterogeneous population with respect to risk of am-
utation and death. The termCLI is poorly defined, as is its natural
istory. Consider that the CLI patients who met accepted hemo-
ynamic definitions and were treated with placebo in the Circulase
Mitsubishi Pharma Corp, Tokyo, Japan) trial exhibited an 87%
imb salvage rate at 6 months,2 similar to the outcomes of patients
reated with endovascular therapy and bypass in the BASIL trial.1
n addition, because of the global epidemic of diabetes, most
ascular specialists are treating an ever-increasing number of dia-
etic individuals with “CLI.” As an aside, it is noteworthy that it
as never intended to apply this term to patients with diabetes
ecause of the confounding factors of neuropathy, ischemia, and
nfection, along with the recognition that people with diabetes
equire higher levels of perfusion for wounds to heal than those
ithout diabetes.3
It seems clear that we will never be able select the most
ppropriate therapy and analyze the outcomes of such therapies for
CLI” until we have better definitions of the input and the output.
ecause CLI constitutes a diverse disease spectrum, a better defi-
ition of the input would require a new classification system that
ncludes gradations of ischemia, wound extent, location, and
epth, as well as infection. With respect to the output, what
utcomes are most clinically important? Patient survival is certainly
ne measure. But what about other outcome measures such as
ajor adverse cardiovascular events, AFS, limb reintervention rate,
elief of pain, wound healing, quality of life, ability to ambulate and
ive independently, and functional status?4,5
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